Source published Aug 23, 2026, 09:29 PM UTC · Operation recorded Aug 27, 2026, 11:52 AM UTC

Moderna's Phase 3 cancer vaccine trial succeeded, with patients on the combination therapy showing longer recurrence-free survival than those on Keytruda alone, and shares surged 177%. This is a material positive catalyst for Moderna.

Source published Aug 23, 2026, 09:29 PM UTC · Operation recorded Aug 27, 2026, 11:47 AM UTC

Moderna reported positive Phase 3 results for its personalized cancer treatment, showing improved recurrence-free survival when combined with Keytruda. This is a material positive catalyst for the company.

Source published Aug 23, 2026, 09:29 PM UTC · Operation recorded Aug 27, 2026, 11:42 AM UTC

Segments 12-15 report that Moderna and Merck's personalized cancer treatment succeeded in a Phase 3 trial, the first large late-stage study of a custom cancer therapy using mRNA technology. Patients receiving the custom shot plus Keytruda went longer without cancer returning or spreading, and Moderna shares closed 177% higher, their largest one-day gain on record. This is a material positive catalyst for Moderna.

Source published Aug 23, 2026, 09:29 PM UTC · Operation recorded Aug 27, 2026, 11:37 AM UTC

Moderna reported positive Phase 3 results for its personalized cancer vaccine, a material positive catalyst that drove a 177% one-day share price increase.

Source published Aug 23, 2026, 09:29 PM UTC · Operation recorded Aug 27, 2026, 11:32 AM UTC

Moderna's Phase 3 cancer vaccine trial succeeded, with patients receiving the custom shot plus Keytruda going longer without cancer recurrence, and shares surged 177%. This is a material positive catalyst for Moderna.

Source published Aug 23, 2026, 09:29 PM UTC · Operation recorded Aug 27, 2026, 11:27 AM UTC

Segments 12-15 report that Moderna's Phase 3 cancer vaccine trial succeeded, with patients receiving the custom shot plus Keytruda going longer without cancer recurrence, and Moderna shares closing 177% higher. This is a material positive catalyst for Moderna.

Source published Aug 23, 2026, 09:29 PM UTC · Operation recorded Aug 27, 2026, 11:22 AM UTC

Moderna and Merck reported positive Phase 3 results for their personalized cancer treatment, with patients receiving the custom shot plus Keytruda going longer without cancer recurrence. This is a material positive catalyst for Moderna.

Source published Aug 23, 2026, 09:29 PM UTC · Operation recorded Aug 27, 2026, 11:17 AM UTC

Moderna reported positive Phase 3 results for its personalized cancer vaccine, a major clinical milestone that drove a 177% stock surge. This is a material positive catalyst for the company.

Source published Aug 23, 2026, 09:29 PM UTC · Operation recorded Aug 27, 2026, 11:12 AM UTC

Moderna reported positive Phase 3 results for its personalized cancer vaccine, showing improved recurrence-free survival when combined with Keytruda. This is a material positive catalyst for the company.

Source published Aug 23, 2026, 09:29 PM UTC · Operation recorded Aug 27, 2026, 11:07 AM UTC

Moderna's Phase 3 cancer vaccine trial succeeded, with patients receiving the custom shot plus Keytruda going longer without cancer recurrence, leading to a 177% stock surge. This is a material positive catalyst for Moderna.